Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Arvinas, Inc. announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis.
Shares of Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The average […]
Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) shares rose 6.6% on Wednesday . The stock traded as high as $33.56 and last traded at $33.44. Approximately 72,271 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 704,842 shares. The stock had previously closed at $31.36. Wall Street Analyst […]
Arvinas, Pfizer Update Phase 1b Trial Data for Vepdegestrant, Palbociclib miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.